Healthcare Jan 10, 2022 11:16 AM (GMT+8) · EqualOcean
On January 10, bluepha, a domestic synthetic biology track enterprise, announced that it had completed the B3 round of financing. So far, the total financing of Series B has reached 1.5 billion yuan. Previously, Lanjing microorganism obtained B1 and B2 rounds of financing with a total of nearly RMB 700 million in February and August 2021 respectively; Series B financing funds will be used for the construction and operation of large-scale production facilities for biodegradable materials PHA and synbio, an industrial 4.0 synthetic biology R & D platform_ The development and deployment of OS, and the R & D and landing of new product pipelines such as regenerative medical materials and engineering probiotics. Founded in 2016 by Dr. Zhang haoqian of Peking University and Dr. Li Teng of Tsinghua University, bluepha is an enterprise engaged in molecular and material innovation based on synthetic biotechnology. It is committed to designing, developing, manufacturing and selling new bio based molecules and materials to help consumer goods, food, medical treatment B-end customers in many industries such as agriculture and industry carry out differentiated competition in the industry. ​ On January 1, 2022, the 25000t / a "super factory", the first product pipeline of cyanine microorganism - biodegradable material PHA, officially started construction in Binhai County, Yancheng City, Jiangsu Province.

This text is a result of machine translation.